Robeco Institutional Asset Management B.V. Sells 6,882 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Robeco Institutional Asset Management B.V. lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 18.8% in the fourth quarter, Holdings Channel reports. The firm owned 29,805 shares of the medical equipment provider’s stock after selling 6,882 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Zimmer Biomet were worth $3,148,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in the business. Geode Capital Management LLC raised its position in Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after acquiring an additional 125,852 shares during the period. M&T Bank Corp raised its holdings in shares of Zimmer Biomet by 48.4% in the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after purchasing an additional 8,709 shares during the period. Peddock Capital Advisors LLC purchased a new position in Zimmer Biomet in the fourth quarter valued at approximately $654,000. National Pension Service grew its holdings in Zimmer Biomet by 3.8% during the third quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock valued at $39,893,000 after purchasing an additional 13,612 shares during the period. Finally, River Global Investors LLP increased its position in Zimmer Biomet by 31.3% in the third quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider’s stock worth $2,276,000 after buying an additional 5,030 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZBH has been the subject of several research reports. Royal Bank of Canada increased their price target on Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, November 4th. Raymond James reduced their target price on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Truist Financial raised their price objective on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Wells Fargo & Company boosted their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, January 29th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Stock Down 1.1 %

Shares of NYSE:ZBH opened at $109.36 on Monday. The firm has a market capitalization of $21.77 billion, a PE ratio of 20.79, a price-to-earnings-growth ratio of 1.90 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a 52-week low of $100.67 and a 52-week high of $133.90. The firm has a fifty day moving average of $107.94 and a 200 day moving average of $108.26.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.